|
Indications and Dosage
Intramuscular
Prevention of herpes zoster Adult: ≥18 years (who are or will be immunodeficient or immunosuppressed): 2 doses of 0.5 mL each given at Month 0 followed by a 2nd dose 1-2 months later. ≥50 years (immunocompetent individuals): 2 doses of 0.5 mL each given at Month 0 followed by a 2nd dose 2-6 months later.
|
|
Reconstitution
Withdraw the entire contents of the vial containing the supplied adjuvant suspension and slowly add into to the vial containing the powder. Swirl gently until the powder is completely dissolved. Do not shake vigorously.
|
|
Contraindications
Severe hypersensitivity (e.g. anaphylaxis).
|
|
Special Precautions
Patient with current or recent febrile illness, thrombocytopenia or any coagulation disorder Not indicated for the treatment of active zoster symptoms or postherpetic neuralgia and prevention of primary varicella infection (chickenpox). Delay vaccination in pregnant women.
|
|
Adverse Reactions
Significant: Syncope (may be accompanied by transient neurological signs e.g. visual disturbance, paraesthesia, and tonic-clonic limb movements), shoulder injury (e.g. shoulder bursitis or tendinopathy), increased risk of Guillain-Barré syndrome.
Gastrointestinal disorders: Abdominal pain, diarrhoea, nausea, vomiting. General disorders and administration site conditions: Fever, fatigue, chills, malaise, inj site reactions (e.g. pain, redness, swelling, pruritus). Musculoskeletal and connective tissue disorders: Myalgia. Nervous system disorders: Headache. Potentially Fatal: Anaphylactoid/hypersensitivity reactions. |
|
Monitoring Parameters
Monitor for anaphylaxis and syncope for 15 minutes following administration.
|
|
Drug Interactions
Immunosuppressive agents may reduce the effectiveness of the vaccine.
|
|
Action
Description:
Mechanism of Action: Recombinant varicella-zoster glycoprotein E antigen vaccine is an inactivated zoster vaccine containing recombinant varicella-zoster virus (VZV) surface glycoprotein E (gE) antigen and an adjuvant (i.e. AS01B). Non-clinical data show that AS01B) induces a local and transient activation of the innate immune system via specific molecular pathways. This facilitates the recruitment and activation of antigen presenting cells carrying gE-derived antigens in the draining lymph node, leading to the generation of gE-specific CD4+ T cells and antibodies. Synonyms: recombinant zoster vaccine (RZV); herpes zoster vaccine (recombinant, adjuvanted). |
|
Storage
Store between 2-8°C. Do not freeze. Protect from light.
|
|
MIMS Class
|
|
References
Anon. Zoster Vaccine (Recombinant). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/12/2021. Anon. Zoster Vaccine Recombinant. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 01/12/2021. Shingrix (GlaxoSmithKline Biologicals SA). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 01/12/2021. Shingrix (GSK Group of Companies). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 01/12/2021. Shingrix Powder and Suspension for Suspension for Injection (GlaxoSmithKline Biologicals S.A). European Medicines Agency [online]. Accessed 01/12/2021. Shingrix Suspension for Intramuscular Injection (GlaxoSmithKline Biologicals). U.S. FDA. https://www.fda.gov. Accessed 01/12/2021.
|
Sign Out
